公开(公告)号：US20150038460A1

公开(公告)日：2015-02-05

申请号：US14515742

申请日：2014-10-16

Applicant: Genentech, Inc.

Inventor： Steven Staben ,  Jianwen Feng ,  Pui Leng Loke ,  Christian A.G.N. Montalbetti

IPC: C07F7/08 ,  C07D491/107 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D403/04 ,  C07D487/04 ,  C07D491/08 ,  C07D401/14 ,  C07D417/14

CPC classification number: C07F7/0805 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D491/08 ,  C07D491/10 ,  C07D491/107

Abstract: The invention relates to novel compounds of Formula I: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.

Abstract translation: 本发明涉及式I的新化合物：其中A，Y，R 1，R 2和下标b各自具有本文所述的含义，式I化合物和立体异构体，几何异构体，互变异构体，溶剂合物，代谢物，同位素，药学上 其可接受的盐或前药。 式I化合物及其药物组合物可用于治疗观察到NF-kB信号传导的不期望或过度活化的疾病和病症。